PETER TASSIOPOULOS APPOINTED CEO OF BIOSIGN

TORONTO, Jan. 10 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) announced today that its Chief Operating Officer, Peter Tassiopoulos, will succeed Radu Leca as Chief Executive Officer effective today. The announcement finalizes a transition process that has been planned for several months. The appointment was proposed by Dr. Leca and unanimously adopted by the Board of Directors. Dr. Leca will continue to serve as the President of Biosign.

Mr. Tassiopoulos has served as Biosign Technologies' Chief Operating Officer since 2009. Mr. Tassiopoulos has over 20 years of experience in business development, sales management, global distribution networks and marketing alliances with Avaya, France Telecom, Bell Canada, Mitel, and GE Healthcare. A recognized expert in digital healthcare technology, Mr. Tassiopoulos has served on various panels at the United Nations, including Mobile Health Management.

"Peter has been actively involved in the leadership and key decisions at Biosign since 2009. He brings relevant business experience, decisive leadership, and continuity to this critical role for the company," said David Silver, Biosign's Chairman. "The Board of Directors deeply appreciates the leadership and contributions that Radu has provided since founding the company in 2006. We are pleased with the serious commitment Peter is making to the company and look forward to Biosign's rapid growth under his leadership."

"Peter is exactly what Biosign needs, at exactly the right time", stated Dr. Leca. "He became my apparent successor in 2009, when he joined us as Chief Operating Officer. Our work together has prepared him for this moment, and I am confident that his tenure will be as remarkable as his conviction and passion for the lasting mark that Biosign will make on healthcare."

"There are remarkable opportunities ahead for Biosign, and I am honored to lead the company through the next chapter of its corporate progression - large-scale commercialization - while enabling Radu to concentrate on advancing our deep product pipeline", said Peter Tassiopoulos.

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

"Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release."

SOURCE Biosign Technologies Inc.

For further information:

Scott Worthington, CFO
Biosign Technologies Inc.
Phone: (416) 218-9800 ext. 224
Email: cfo@biosign.com
                  Alan S. Roemer, SVP
The Trout Group LLC
Phone: 646 378-2900
Email : aroemer@troutgroup.com

Profil de l'entreprise

Biosign Technologies Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.